Neurologic Outcomes in People with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Exposed To Immune Checkpoint Inhibitors

Drs. Shuvro Roy and Alexander Gill discuss the impact of immune checkpoint inhibitors on individuals with multiple sclerosis and neuromyelitis optica spectrum disorder, questioning the safety of this therapy. They highlight varied outcomes between the two cohorts, noting the rarity of ICI-associated disease activity in older MS patients and the potential for severe myelitis in NMOSD patients.